LEMAITRE VASCULAR INC(LMAT)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
LEMAITRE VASCULAR INC (LMAT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LMAT at 66.0/100 on a 32-signal composite quality model, placing it at rank #448 of 2,960 stocks — the top 25% of the AI-ranked universe. LMAT scores in the top quartile across profitability (88.4), balance sheet strength (87.0), free cash flow (82.0). Areas of concern include revenue scale (27.5) and institutional flow (35.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 31.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), LEMAITRE VASCULAR INC reports quarterly revenue of $70.4M, net income of $17.1M, an operating margin of 29.0%. Top institutional holders of LMAT by reported 13-F value include BlackRock, Conestoga Capital Advisors, FIRST ADVISORS, based on the most recent SEC filings. LMAT trades on the Nasdaq exchange and files with the SEC under CIK 1158895. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LMAT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for LEMAITRE VASCULAR INC directly from SEC EDGAR.
AI Quality Score
66.0/100
AI Rank
#448
Revenue
$70.4M
Net Income
$17.1M
Free Cash Flow
$13.7M
Operating Margin
29.0%
LMAT key financials by period
LEMAITRE VASCULAR INC reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$249.6M
$57.7M
27.2%
FY 2024
10-K
$219.9M
$44.0M
23.8%
FY 2023
10-K
$193.5M
$30.1M
19.0%
FY 2022
10-K
$161.7M
$20.6M
16.6%
FY 2021
10-K
$154.4M
$26.9M
23.6%
FY 2020
10-K
$129.4M
$21.2M
22.3%
Institutions holding LMAT
Institutional investors reporting a position in LEMAITRE VASCULAR INC on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Net sales rose 10% YoY to $70.4M with gross margin up 210bps to 72.1%, as growth was broad-based across all three geographies led by grafts and shunts.
Biggest Revenue Drivers
Americas$43.5M+5% YoY
Increased sales of grafts, shunts, and patches, offset by decreased catheter sales
Europe, Middle East and Africa$22.1M+18% YoY
Increased sales of grafts, shunts, patches, and valvulotomes, offset by decreased catheters
Biggest Revenue Drivers
Total revenue: $70.4M+10% YoY
Americas$43.5M+5% YoY
Increased sales of grafts, shunts, and patches, offset by decreased catheter sales
Europe, Middle East and Africa$22.1M+18% YoY
Increased sales of grafts, shunts, patches, and valvulotomes, offset by decreased catheters
Asia Pacific$4.8M+18% YoY
Increased sales of clips, grafts, and catheters
Largest Expense Items
Sales and marketing$14.4M-3% YoY
Lower compensation, commissions, and contest expenses
General and administrative$11.1M+7% YoY
Higher headcount and wage-driven compensation, and increased professional fees
Research and development$4.8M+37% YoY
Higher third-party service fees and supplies for the allograft tissue transfer to Burlington, plus new Billerica warehouse start-up costs
Margins: Gross margin rose 210bps to 72.1%, driven by sales price increases, favorable product mix, and lower shipping costs, partially offset by unfavorable manufacturing efficiencies and higher excess and obsolescence charges.
Watch Items from the Filing
FDA issued a warning letter after an April 2025 Artegraft facility inspection; a June 2026 re-inspection identified additional new observations, with remediation ongoing.
Biologics represented 55% of worldwide sales in Q2 2026, a significant concentration in a product category the company calls differentiated and growing.
Direct-to-hospital sales were 95% of total net sales in the quarter, reflecting the company's strategy of transitioning distributor markets to direct sales.
$172.5M of 2.50% convertible senior notes outstanding; conversion price adjusts downward each time the quarterly dividend exceeds $0.16/share, currently $0.25.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
